Video

Dr. Jain Discusses Treatment of Richter's Transformation in CLL

Author(s):

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with chronic lymphocytic leukemia who have developed Richter’s transformation.

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with chronic lymphocytic leukemia (CLL) who have developed Richter’s transformation.

Richter’s transformation remains an unmet medical need, says Jain. Most of the targeted therapies for CLL have not been successful in patients with Richter’s transformation.

Checkpoint blockade is a valid concept, Jain says, as well as chimeric antigen receptor (CAR) T-cell therapies—studies of which will come out in the next few years.

Related Videos
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Tiago Biachi, MD, PhD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Elias Jabbour, MD
Daniel DeAngelo, MD, PhD
Douglas W. Sborov, MD, MS